Geode Capital Management LLC raised its stake in shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 7.6% in the third quarter, Holdings Channel reports. The institutional investor owned ...

State Street Corp increased its stake in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 2.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor ...

After-Hours Stock Movers: IGM Biosciences (NASDAQ:IGMS) fell 21% after it announced plans to to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing... IGM Biosciences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a recent series of transactions, Baker Bros. Advisors LP, a significant shareholder in IGM Biosciences, Inc. (NASDAQ:IGMS), has made substantial purchases of the company's... In recent trading ...

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD) to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance ...

Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. Gilead is buying the additional Assembly Bio stock ...

Steven Weber, Principal Accounting Officer at IGM Biosciences, Inc. (NASDAQ:IGMS), recently sold 539 shares of the company’s common stock. The transaction, which took place on December 16 ...

IGM Biosciences, Inc. (NASDAQ:IGMS) Chief Executive Officer Mary Beth Harler has sold shares of the company's stock, according to a recent regulatory filing. The transaction comes as the stock ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs.